Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Daratumumab + Gene Therapy by Indapta Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
Daratumumab + Gene Therapy is under clinical development by Indapta Therapeutics and currently in Phase II for Relapsed Multiple Myeloma....
Data Insights
Daratumumab + Gene Therapy by Indapta Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
Daratumumab + Gene Therapy is under clinical development by Indapta Therapeutics and currently in Phase II for Non-Hodgkin Lymphoma. According...